{"id":708084,"date":"2026-06-01T10:48:14","date_gmt":"2026-06-01T10:48:14","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/708084\/"},"modified":"2026-06-01T10:48:14","modified_gmt":"2026-06-01T10:48:14","slug":"this-asx-healthcare-rocket-is-up-14-in-a-week-heres-why-investors-are-still-buying","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/708084\/","title":{"rendered":"This ASX healthcare rocket is up 14% in a week. Here\u2019s why investors are still buying"},"content":{"rendered":"

4DMedical Ltd\u00a0(ASX: 4DX<\/a>) shares are pushing higher on Monday after the medical imaging tech company announced a European acquisition. <\/p>\n

At the time of writing, the 4DMedical share price is up 4.28% to $4.14, after reaching an intraday high of $4.29 in early morning trade.<\/p>\n

The move adds to a huge run for shareholders, with 4DMedical shares now up around 14% over the past week and more than 1,100% since this time last year. <\/p>\n

Let’s take a closer look at today’s announcement. <\/p>\n

\"Medical<\/p>\n

Image source: Getty Images<\/p>\n

4DMedical pushes into Europe<\/p>\n

According to the\u00a0release<\/a>, 4DMedical has entered a binding agreement to acquire contextflow GmbH, a Vienna-based medical technology company focused on lung cancer screening and advanced AI-driven imaging.<\/p>\n

The deal gives 4DMedical an immediate commercial and clinical platform in Europe, adding a third major region to its existing operations in North America and Australia and New Zealand. <\/p>\n

The acquisition includes a CE-marked lung cancer screening product already deployed in Europe. It uses nodule detection technology and is expected to sit alongside 4DMedical’s existing lung imaging software.<\/p>\n

Management said the deal gives the company an immediate entry point into Europe’s respiratory and thoracic imaging market, which it estimates at US$1.5 billion to US$2 billion.<\/p>\n

More on the European deal<\/p>\n

The deal also looks relatively small against 4DMedical’s current cash position.<\/p>\n

4DMedical will pay 1.12 million euros, or about $1.86 million, in cash, along with 56,235 shares upfront.<\/p>\n

The agreement also includes a potential earnout of up to 2.59 million zero-exercise-price options if performance milestones are met.<\/p>\n

The upfront cash component will be funded from 4DMedical’s existing cash reserves, while the acquired business is expected to retain 19 million euros, or about $30.8 million, in accumulated tax losses.<\/p>\n

Those losses may be used to offset future taxable income generated by the Austrian business.<\/p>\n

Management described the acquisition as a capital-efficient way to enter a large healthcare market.<\/p>\n

Founder and Managing Director Andreas Fouras said the deal gives 4DMedical a European platform in a market roughly half the size of the United States. <\/p>\n

He also said the acquisition increases the company’s market opportunity by about 50%, while using only 6.5% of its existing cash balance. <\/p>\n

Foolish Takeaway<\/p>\n

4DMedical has become one of the ASX’s standout healthcare stocks over the past year.<\/p>\n

The company now has a\u00a0market capitalisation<\/a>\u00a0of about $2.46 billion, even though it remains loss-making on an\u00a0earnings per share (EPS)<\/a>\u00a0basis. <\/p>\n

The next test is whether 4DMedical can turn its growing footprint into stronger commercial adoption across the US, Europe, and ANZ.<\/p>\n","protected":false},"excerpt":{"rendered":"4DMedical Ltd\u00a0(ASX: 4DX) shares are pushing higher on Monday after the medical imaging tech company announced a European…\n","protected":false},"author":2,"featured_media":41788,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,137,500],"class_list":["post-708084","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-au","tag-australia","tag-health","tag-healthcare"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/708084","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=708084"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/708084\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/41788"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=708084"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=708084"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=708084"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}